A Phase 1, Double Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 388626 Administered to Healthy Volunteers - Phase 1 Study with Single and Multiple Doses of ISIS 388626
A Phase I , Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 388626 Administered to Healthy Volunteers
The primary purpose of this trial is to assess the safety and tolerability of ISIS-SGLT2Rx when given at increasing single doses and to assess the safety and tolerability of the same doses when given multiple times.
100 项与 ISIS-388626 相关的临床结果
100 项与 ISIS-388626 相关的转化医学
100 项与 ISIS-388626 相关的专利(医药)
100 项与 ISIS-388626 相关的药物交易